Investing in the future of medicine: A look at Novo Nordisk, NetraMark Holdings and Evotec

Novo Nordisk – In transition

Danish pharmaceutical giant Novo Nordisk is undergoing a decisive phase of transformation. After years of hypergrowth driven by its blockbuster GLP-1 drugs, the Company recently announced a comprehensive cost-cutting program. The plan is to cut around 9,000 jobs, which corresponds to about 11% of the workforce. At the same time, the profit forecast for the current year was lowered. However, these measures are less a sign of weakness and more of a strategic realignment. Management is responding to a changing market that is increasingly characterized by price pressure and intensified competition.

Competition in the lucrative GLP-1 sector has increased noticeably. The US market, Novo's most important single region, is developing more dynamically than expected. While demand for Novo's own portfolio of Wegovy and Ozempic remains strong, competitor Eli Lilly is gaining market share with Zepbound. At the same time, insurers and health insurance companies are putting pressure on prices. Novo is responding with its own price promotions and is attempting to maintain a cost advantage through long-term capacity investments in production. The recent addition of Wegovy to the Medicare benefits catalog could also further fuel patient demand.

The Company is firmly committed to modern technologies as game changers. It is investing heavily in artificial intelligence in particular to give research and development a significant boost. The aim is to use AI-based models to identify new drug candidates more quickly while making clinical trials more efficient. This data-driven approach also extends to production and market analysis. For investors, this signals that the Company is not only optimizing costs in the short term, but also aims to position itself as an innovative technology leader in healthcare in the long term. The share price has fallen slightly in recent days and currently stands at EUR 46.12.

NetraMark Holdings – AI in clinical research

The development of new drugs remains a highly costly and risky undertaking. The majority of active ingredients that enter clinical trials ultimately fail. Late-stage failures in Phase 3 studies are particularly expensive. This is where NetraMark Holdings steps in with an unconventional AI approach. Instead of relying on historical data like others, the NetraMark platform analyzes individual patient data from the customer's own ongoing or completed studies. This generates thousands of data points per patient, which can hardly be fully evaluated using conventional methods. The AI combs through this data jungle to uncover hidden patterns and subgroups that are relevant to the success of the therapy or side effects. These insights help design future studies in a more targeted manner.

An important step for the credibility of any healthtech solution is recognition by the FDA. NetraMark has secured a date for a Critical Path Innovation Meeting for this purpose. This meeting is not for approval, but is intended to provide a roadmap for the regulatory integration of the technology. A positive response from the agency would send a strong signal to the market. Commercially, the Company is pursuing a dual strategy of direct sales to pharmaceutical companies and an exclusive partnership with the CRO Worldwide Clinical Trials. This alliance is smart, as CROs manage the operational aspects of the majority of all clinical trials. Integration into their study processes paves the way for initial revenues.

Beyond core analytics, NetraMark is developing additional tools based on the same AI infrastructure. For example, one software tool supports real-time verification of recruited patients against those considered ideal profiles by the AI. Another tool monitors the performance of individual study centers and warns of deviations. The addressable market volume is enormous. The clinical trial support sector is estimated at around USD 47 billion. The foundation has been laid. Now it is a matter of converting the promising pipeline into concrete commercial success. If this succeeds, the Company could become a major player in the pharmatech sector. The stock is currently trading at CAD 1.46.

Evotec - Focus on strategy change despite index decline

The impending departure from the MDAX is weighing on sentiment at Evotec. Index funds have to restructure their positions, which is putting additional pressure on the share price. Despite this technical effect, there are fundamental developments that investors are keeping an eye on. A recent analyst commentary confirmed the positive outlook, but lowered the price target. The reason for the cautious confidence is the ongoing challenges in the core business, while the strategic realignment is making progress.

There is a division in the operating business. While the traditional research area (D&PD) is suffering from weak demand, the biologics division (JEB) is growing significantly. The planned sale of the Toulouse site to Sandoz underscores the strategic shift toward a less capital-intensive model. This is where artificial intelligence comes into play, helping to evaluate large patient databases in order to accelerate drug discovery and develop more precise therapeutic approaches.

Despite the current challenges, management remains committed to achieving its EBITDA targets. By focusing on high-margin areas such as biologics and the use of data-driven technologies, the Company aims to achieve sustainable, profitable growth. Although the index change is a setback, the strategic transformation could set the course for successful repositioning in the market in the long term. CEO Dr. Christian Wojczewski bought shares worth around EUR 296,000 at a price of EUR 5.92 at the end of August, which can be seen as a positive sign. The share is currently available for EUR 5.94.

Investing in the future of medicine requires a differentiated perspective. As a transforming giant, Novo Nordisk is mastering the balancing act between cost discipline and technological offensive in order to defend its market leadership. NetraMark Holdings scores with a unique AI approach that could reduce the immense risk of clinical trials and disruptively change the entire development process. Meanwhile, Evotec must overcome its operational weakness and prove that its focus on biologics and data-driven research will drive strategic change. Together, they show that AI is the key, but the path to success remains individual.